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21 ABSTRACT
2 Poly(amidoamine) dendrimer (PAMAM) is well known for its high efficiency as a drug 
3 delivery vehicle. However, the intrinsic cytotoxicity and lack of a detectable signal to facilitate 
4 tracking have impeded its practical applications. Herein, we have developed a novel label-free 
5 fluorescent and biocompatible PAMAM derivative by simple surface modification of PAMAM 
6 using acetaldehyde. The modified PAMAM possessed a strong green fluorescence, which was 
7 generated by the C=N bonds of the resulting Schiff Bases via n-π* transition, while the intrinsic 
8 cytotoxicity of PAMAM was simultaneously ameliorated. Through further PEGylation, the 
9 fluorescent PAMAM demonstrated excellent intracellular tracking in human melanoma 
10 SKMEL28 cells. In addition, our PEGylated fluorescent PAMAM derivative achieved 
11 enhanced loading and delivery efficiency of the anticancer drug doxorubicin (DOX) compared 
12 to the original PAMAM. Importantly, the accelerated kinetics of DOX-encapsulated 
13 fluorescent PAMAM nanocomposites in an acidic environment facilitated intracellular drug 
14 release, demonstrating comparable cytotoxicity to that of the free-form doxorubicin 
15 hydrochloride (DOX·HCl) against melanoma cells. Overall, our label free fluorescent 
16 PAMAM derivative offers a new opportunity of traceable and controlled delivery for DOX and 
17 other drugs of potential clinical importance.
18 KEY WORDS
19 Label-free fluorescence, PAMAM, Drug delivery, Intracellular tracking, Doxorubicin
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31 1 INTRODUCTION
2 Dendrimers, a notable class of highly branched synthetic macromolecules, hold great promise 
3 for developing nano-sized drug delivery systems (DDS) with specially designed targeting 
4 functions and controlled release capabilities for therapeutic applications in cancer, 
5 neurodegeneration and cardiovascular disease1-4. In particular, poly(amidoamine) (PAMAM) 
6 dendrimers have attracted increasing interest as excellent candidates for DDS, due to their 
7 controllable molecular size, monodispersity and abundant surface functional groups5-8. To 
8 facilitate mechanistic studies and optimization of carrier design and delivery efficiency, it is 
9 practically required that the DDS have detectable signals to be traced intracellularly and in real 
10 time9, 10. However, the pristine PAMAM dendrimer is a non-fluorescent macromolecule, 
11 although, fluorescent labelling can be used  to overcome this problem11, these approaches result 
12 in changes in surface charge, solubility, biocompatibility and other physicochemical properties 
13 as well as limiting the potential for further surface modification and functionalization. 
14 Additionally, the cost, biosafety and disposal of labelling fluorescent materials present other 
15 problems in their practical applications12, 13. In last few years, researchers have reported several 
16 non-traditional  intrinsic blue luminescence PAMAM dendrimers for biological applications 
17 and demonstrated that the emission intensity can be enhanced by lowering pH14-16, oxidation 
18 protocols14, 17 or surface chemistry engineering16. In particularly, surface chemistry engineering 
19 is deemed to be the most realistic strategy for designing high emission intensity materials since 
20 lowing pH or oxidation protocols can be fatal for in vivo systems due to protein denaturation 
21 and ROS generation16. Plenty of micro molecules such as mannose18, 3-aminobenzeneboronic 
22 acid19 and 4-carbomethoxy pyrrolidone20 have been successfully applied to PAMAM to 
23 fabricate high inherent blue fluorescent PAMAM dendrimers with excellent biocompatibility 
24 and imaging capabilities. However, those chemistry engineered blue fluorescent dendrimers 
25 usually require UV excitation, which poses major limitations in its application since UV is 
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41 harmful to living cells and biological systems21. Also, the cells and tissues may become auto-
2 fluorescent when excited by UV/Vis radiation of suitable wavelength, which may also hinder 
3 the practical application of blue fluorescent PAMAM dendrimers in biological system22. To 
4 our knowledge, relatively little research has reported other colored (green, red) inherent 
5 fluorescent PAMAM. Therefore, it remains a crucial challenge to develop powerful label-free 
6 fluorescent PAMAM dendrimer for PAMAM-based DDS.
7 Herein, we developed a label-free green fluorescent PAMAM dendrimer by surface 
8 modification of pristine PAMAM with acetaldehyde to generate new traceable and controllable 
9 DDS (Scheme 1). Through the aldehyde-ammonia reaction, the terminal primary amino groups 
10 in PAMAM were replaced by Schiff base terminals. The modified PAMAM exhibited strong 
11 green fluorescence with a maximum emission at 507 nm and maximum excitation at 485 nm 
12 due to the n-π* transition of the C=N bonds in the resulting Schiff bases23. Attractively, this 
13 fluorescence behaviour was pH-independent, which was highly desirable for applications in 
14 biological systems. Furthermore, the intrinsic cytotoxicity of PAMAM, caused by high positive 
15 charge of the terminal amines, was substantially decreased24, since replacement  of amines by 
16 Schiff base terminals neutralized the overall surface charge. To ensure stability of the label-
17 free fluorescent PAMAM in biological media, PEGylation was performed to introduce steric 
18 hindrance that prevented aggregation of the nanocarriers25-27, and afforded excellent 
19 biocompatibility in different cell lines. Traceability of the fluorescent PAMAM was also 
20 demonstrated in cells using confocal microscopy and flow cytometry. Furthermore, a model 
21 drug, doxorubicin (DOX),was encapsulated into our new nanocarriers by a precipitation 
22 method, and drug release kinetics were evaluated at different pH values28. To evaluate cancer 
23 cell uptake and therapeutic efficacy, SKMel28 cells were used. Our optimized nanocomposites 
24 showed higher drug uptake efficacy and better therapeutic efficacy compared to hydrophobic 
25 DOX and PAMAM G5/DOX (G5/DOX) composites, respectively. These results demonstrate 
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51 that this newly developed modified PAMAM is an improved DDS with potential clinical 
2 applicability.
3
4 Scheme 1. (a) A schematic description of preparing label free fluorescent poly(amidoamine) 
5 dendrimer (F-G5-PEG) and its properties for drug delivery. (b) Intracellular behavior of DOX 
6 loaded F-G5-PEG. 
7 2 Materials and methods
8 2.1 Materials
9 Ethylenediamine core amine-terminated generation 5 PAMAM dendrimers (G5), 
10 acetaldehyde, triethylamine (TEA) and doxorubicin hydrochloride (DOX·HCl) were 
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61 purchased from Sigma-Aldrich (NSW, Australia). Methoxy-PEG-Succinimidyl 
2 Carboxymethyl Ester (M-SCM-2000; Mw 2000) was purchased from Jenkem Technology 
3 (Beijing, China). Amicon® Ultra Centrifugal Filters (10 KD) were purchased from Merck 
4 Millipore (VIC, Australia). Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased 
5 from Thermo Fisher Scientific (NSW, Australia), Endothelial Cell Growth Basal Medium-2 
6 (EBM-2) was purchased from Lonza (Melbourne, Australia). VECTASHIELD® mounting 
7 medium was purchased from Vector Laboratories (US). (3-(4,5-dimethylthiazol-2-yl)-2,5-
8 diphenyltetrazolium bromide (MTT) was purchased from Life Technologies (NSW, Australia). 
9 Other routine chemicals were obtained from Sigma-Aldrich and used as received. The water 
10 used in all the experiments was purified using a Milli-Q Plus 185 water purification system 
11 (Millipore) with a resistivity higher than 18 MU cm.
12 2.2 Synthesis of label-free Fluorescent PAMAM G5
13 The label-free fluorescent PAMAM G5 (F-G5) was synthesized by the reaction of acetaldehyde 
14 with amine-terminated G5 at room temperature. G5 (100 mg; 7 mmol) was dissolved in Milli-Q 
15 water (10 mL) and adjusted to pH 10 using NaOH solution (0.1 M). Acetaldehyde (in excess) 
16 was added dropwise to the G5 solution. The reaction mixture was protected from light and 
17 stirred at room temperature for 8h, followed by centrifugation using Amicon® filters at 4500 
18 rpm for 30 min to remove any unreacted acetaldehyde. The purification process was repeated 
19 3 times. The purified solution of F-G5 dendrimer was stored at 4 oC for further use.
20 2.3 PEGylation of F-G5
21 The prepared F-G5was covalently conjugated with M-SCM-2000 via an NHS ester coupling 
22 reaction, with the feed molar ratio of 1:30. M-SCM-2000 (2.1 µmol) dissolved into 5 mL water, 
23 to which 0.07 µmol F-G5 was added quickly. The mixture was kept at room temperature and 
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71 magnetically stirred for 4 h, followed by centrifugation using Amicon filters (4500 rpm for 30 
2 min; repeated 4 times) to remove any unreacted M-SCM-2000. The purified solution of 
3 PEGylated F-G5 (F-G5-PEG) was stored at 4 oC for further use.
4 2.4 Qualification analysis of F-G5 and F-G5-PEG 
5 Qualification analysis of F-G5 and F-G5-PEG was performed by NGC™ Medium-Pressure 
6 Liquid Chromatography Systems. Briefly, 0.5 mL G5, F-G5 or F-G5-PEG (1mg/mL in PBS, 
7 pH=7.4) was analysed by the gel filtration using an EnrichTMSEC650 (Bio-Rad) column and 
8 NGC purifier (Bio-Rad). Bovine Serum Albumins (BSA, Sigma, MW~ 66K) was used as 
9 reference protein. 0.1M PBS (pH=7.4) containing 5% glycerol was used as elution buffer.
10 2.5 Encapsulation of DOX within F-G5-PEG
11 DOX was encapsulated inside F-G5-PEG using a solvent-displacement (nanoprecipitation) 
12 method slightly modified from literature29. F-G5-PEG (0.07 µmol) was dissolved in 3 mL 
13 water, while 0.7 µmol DOX·HCl was dissolved in 0.4 mL methanol and neutralized 
14 sequentially with 3.5, 5.25, 7µmol triethylamine (TEA) to generate hydrophobic DOX. The 
15 hydrophobic DOX solution was then added dropwise into F-G5-PEG solution and magnetically 
16 stirred overnight to evaporate excess methanol and TEA. The F-G5-PEG/DOX solution was 
17 centrifuged at 10,000 rpm for 10 min, to precipitate non-encapsulated free DOX (as free DOX 
18 is water insoluble). The precipitation was collected and dissolved into 5 mL methanol, followed 
19 by quantity analysis based on the DOX absorbance intensity at 480 nm via UV-visible 
20 measurement. G5/DOX nanocomposites were also prepared using the same protocol with the 
21 same molar ratio of G5 to DOX.
22 2.6 Characterisation
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81 Transmission electron microscopy (TEM) was carried out using a CM10 (Philips) system at an 
2 acceleration voltage of 120 kV. F-G5-PEGwas diluted to 0.5 mg/ml in Milli-Q water and 
3 sonicated for 10 min, dropped onto carbon-coated copper grids, followed by negative staining 
4 using 2% Uranyl Acetate. UV-vis absorption spectra were recorded on a UV-2600 
5 spectrophotometer (Shimadzu, Japan). Fluorescent emission and excitation spectra were 
6 recorded on a Fluorolog spectroscopy (Horiba, Australia). Fourier transform infrared (FTIR) 
7 spectra were taken on a NICOLET 6700 FTIR spectrometer (Thermo Scientific, Australia) at 
8 room temperature. The particle sizes and zeta potentials were measured at room temperature 
9 using a Zetasizer Nano ZS (Malvern, Australia) equipped with the ZET 5104 cell. 1H Nuclear 
10 Magnetic Resonance (NMR) experiments were recorded using a 400 MHz Bruker NMR in 
11 D2O.
12 2.7 Kinetic Release Study
13 F-G5-PEG/DOX nanocomposites and free DOX (50 µg equivalent DOX in 2 mL phosphate 
14 buffered saline (PBS), pH 7.4, 6.0 or 5.0) were placed in a dialysis bag with molecular weight 
15 cut-off (MWCO) of 10,000, hermetically tied, and suspended in 8 mL PBS buffer (pH 7.4, 6.0 
16 or 5.0). The entire system was kept in a constant-temperature vibrator at 37 oC. Then, at each 
17 predetermined time point, 0.2 mL dialysis buffer was removed for measurement, and 0.2 mL 
18 PBS (at the corresponding pH) was added back to keep the total volume of the dialysis buffer 
19 constant. The released DOX was quantified by a microplate reader (PHERAstar FS, Australia) 
20 that measured the DOX fluorescence (λex = 480 nm, λem = 580 nm). The cumulative release 
21 (Cr) of DOX at each time point was obtained according to the equation
22 Cr = Wt/Wtot × 100% 
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91 where Wt and Wtot are the cumulative amount of released drug at time t and the total amount 
2 of encapsulated drug in the nanocomposites used in dialysis, respectively.
3 2.8 Cell Culture
4 SKMel28 cell line was obtained from the American Type Culture Collection (ATCC). Cells 
5 were cultured in DMEM supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich), 
6 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Sigma-Aldrich), 4 mM 
7 L-Glutamine (Sigma-Aldrich), 100 U/mL penicillin, and 100 U/mL streptomycin (Life 
8 Technologies). hCMEC/D3 cell line was obtained from ATCC. Cells were cultured in EMB-2 
9 medium (Lonza, Melbourne) supplemented with 5% FBS, 10 mM HEPES, 100 U/mL 
10 penicillin, and 100 U/mL streptomycin and 1 ng/mL basic fibroblast growth factor (Bfgf, 
11 ThermoFisher). HEK293 and NSC34 cell lined were obtained from ATCC. Cells were cultured 
12 in DMEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 U/mL 
13 streptomycin. Cultures were maintained at 37 oC in a wet incubator with 5% CO2, and the 
14 medium was replaced every 3 days.
15 2.9 Cytotoxicity Test
16 To test biocompatibility, SKMel28, hCMEC/D3, HEK293 and NSC34 cells were cultured in 
17 96-well plates at density of 5000 cells/well and allowed to adhere overnight at 37 oC in a 
18 humidified 5% CO2-containing atmosphere. Growth media were replaced with media 
19 containing G5, F-G5, or F-G5-PEG. The cells were then incubated for 48 h before 20 µL MTT 
20 (5.0 mg/mL in PBS) was added to each well and further incubated for 4 h at 37 oC. The media 
21 was then removed and 150 µL of dimethyl sulfoxide (DMSO) was added to each well to ensure 
22 complete solubilization of formazan crystals before cell viability was determined by absorption 
23 at 560 nm.
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10
1 To test therapeutic efficacy, SKMel28 cells were cultured in 96-well plates at density of 
2 5000 cells/well and allowed to adhere overnight at 37 oC in a humidified 5% CO2-containing 
3 atmosphere. Growth media were replaced with DMEM containing DOX·HCl, DOX (TEA-
4 treated), G5/DOX or F-G5-PEG/DOX at equivalent DOX concentrations range from 0.1 to 5 
5 µg/mL. The cells were then incubated for 48 h, followed by MTT assay as described above. 
6 2.10 Intracellular Tracking of F-PAMAM
7 SKMel28 cells were seeded at a concentration of 1×105 cells/well in 6-well plates containing 
8 slide cover glasses (24×24 mm), and cultured at 37 oC for 24 h. F-G5-PEG was added to the 
9 cell culture media to obtain a final concentration of 50 µg /mL for each well, and cells further 
10 incubated at 37 oC for 2, 4, 8 or 24 h. Cells were then washed with PBS followed by adding 1 
11 mL Hoechst 33342 solution (Thermofisher, 1:2000 in PBS) and incubated for 10 minutes 
12 (protected from light). After Hoechst staining, cells were washed with PBS again and stained 
13 with Cytopainter (Abcam, ab176827) following the manufacturer's protocol. Live cell imaging 
14 was performed using a Zeiss LSM 880 laser-scanning confocal microscope. 
15 2.11 Intracellular Drug Delivery
16 Intracellular drug delivery was assessed using a combination of cellular imaging and flow 
17 cytometry. For cellular imaging, SKMel28 cells were seeded at a concentration of 1×105 
18 cells/well in 6-well plates containing glass slide covers and cultured at 37 oC for 24 h. Next, 
19 DOX·HCl, DOX (TEA-treated), G5/DOX or F-G5-PEG/DOX were added to culture media to 
20 obtain a final DOX concentration of 2.5 µg/mL. Cells were then incubated at 37 oC for 4 h, 
21 followed by washing with PBS (x 3) to remove non-cell incorporated drug.  Subsequently, cells 
22 were fixed with 4 % paraformaldehyde solution and treated with VECTASHIELD® mounting 
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1 medium with DAPI for 10 min at room temperature. Cells were imaged by a Zeiss LSM 880 
2 laser-scanning confocal microscope.
3 For flow cytometry, SKMel28 cells were seeded at a concentration of 1×105 cells/well in 6-
4 well plates and cultured at 37 oC for 24 h. Next, DOX·HCl, DOX (TEA-treated), G5/DOX or 
5 F-G5-PEG/DOX were added to culture media to obtain a final DOX concentration of 2.5 
6 µg/mL. Cells were then incubated at 37 oC for 4 h, followed by washing with PBS (x3) to 
7 remove non-cell incorporated drug. Subsequently, cells were detached by trypsin, collected and 
8 concentrated, and then fixed with 4 % paraformaldehyde at 4 oC overnight. The cells were 
9 analysed by a flow cytometer (BD LSR Fortessa X-20, Australia) using FITC and PE channels 
10 to quantify the amounts of F-PAMAM and DOX, respectively, in individual cells. 
11 Quantification was performed using standardized reference solutions of F-G5-PEG and 
12 DOX·HCl. 
13 2.12 Statistical Analysis
14 One-way ANOVA was performed using Origin 8.0 software to compare the cytotoxicity of 
15 cells treated with different materials. The significance level was set as 0.05, and the data were 
16 indicated with (**) for p<0.01 and (***) for p<0.001. Data are expressed as the mean ± 
17 standard deviation. Each experiment was performed in triplicate. 
18 3 RESULTS AND DISCUSSION
19 3.1 Physical and Optical Properties of F-PAMAM and PEGylated F-PAMAM
20    G5 PAMAM dendrimer was selected for the synthesis of label-free fluorescent dendrimer 
21 due to its relative small size (5.4 nm, theoretical value), monodispersity, large internal cavity 
22 and numerous functionable amine groups30, 31. As shown in schematic 1, the label free 
23 fluorescent PAMAM (F-G5) was fabricated by simple surface modification using 
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1 acetaldehyde. After 8 h reaction the colorless PAMAM turned to brown (Fig S1), indicating 
2 successful formation of Schiff base12, 32, 33. PEG (M-SCM-2000) was then conjugated to the 
3 surface of F-G5 by classical esterification between N-hydroxysuccinimide (NHS) ester and 
4 primary amino groups contained in F-G5. The F-G5 and PEGylated F-G5 (F-G5-PEG) were 
5 further characterized by TEM, DLS, FTIR, Liquid Chromatography and 1H NMR.
6 TEM images in Fig 1a and Fig S1 showed that F-G5-PEG had a relative uniform particle 
7 size of approximately 22 nm while G5 had a particle size of approximately 16 nm in water and 
8 approximately 5 nm in methanol. The size of nanoparticles was also acquired with DLS 
9 measurement. As shown in Fig 1b, the initial size of G5 was 6.6±0.4 nm (Close to theoretical 
10 value). After aldehyde modification, the size of F-G5 changed to 5.1±1.1nm, which was 
11 smaller than G5. After PEGylation the size of F-G5-PEG increased to 9.8±0.6 nm, which was 
12 mainly caused by the grafting of PEG chain. When compared the TEM results (sample prepared 
13 in water) with DLS, we found that the size of G5 and F-G5 from TEM was significantly larger 
14 than the number size distribution of DLS and theoretical value, the increased size may be 
15 caused by the formed non-uniform particle deposition and particle aggregation of dendrimers 
16 by the hydrogen interaction in the aqueous solution during drying step34, 35. The TEM image of 
17 G5 in methanol was around 5 nm (Fig S1) (close to theoretical value) might be an evidence of 
18 the above hypothesis. We further analysed the zetapotential by DLS, as seen in Fig 1c, 
19 compared with G5, the zeta potential of F-G5/F-G5-PEG showed a significant charge decrease 
20 from +28.2 to approximately +4.8 mV. This decreased surface charge was likely primarily due 
21 to the replacement of amino groups with non-charged Schiff base terminals and mPEG.
22     FTIR was next used to characterize the surface functionalization of F-G5 and F-G5-PEG. 
23 As displayed in Fig S2, the peaks at 2970, 2873 and 1374 cm-1 indicated the presence of -CH3 
24 groups, suggesting the successful introduction of the Schiff base (-N=CH-) structure on the 
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1 PAMAM surface. The peaks at 2880 and 1098 cm-1 indicated the presence of C-O-C and 
2 confirm the successful conjugation of PEG on the surface of label free fluorescent dendrimer. 
3 The absorption peaks due to adsorbed H2O around 1623 cm-1 may potentially overlap with the 
4 absorption peaks of -N=C- group and amide I, which are normally observed at 1615~1700 
5 cm-1. 
6 The chemical structure of each dendrimer product and intermediate was also characterized 
7 by1H NMR spectroscopy. The spectra of F-G5 and F-G5-PEG were collected to further 
8 confirm the successful introduction of various functional groups to the G5 dendrimer. As 
9 shown in Fig S3, the chemical shifts of F-G5 at 1.83 and 8.37 ppm were assigned to -CH3 and 
10 -N=CH- groups respectively, demonstrating the successful incorporation of the Schiff base 
11 structure to PAMAM G5. As calculated from NMR spectrum, around 31.7% amino groups 
12 were replaced by -N=C-CH3 groups. The chemical shifts of F-G5-PEG at 3.63 ppm were 
13 assigned to -CH2-CH2- repeat segments and indicate the successful conjugation of PEG on the 
14 surface of F-G5. The chemical shift peak of F-G5-PEG at 2.71 ppm assigned to -NHS was no 
15 longer detected, indicating that the NHS had completely reacted with F-G5. However, the 
16 chemical shift peak of F-G5-PEG at1.83 and 8.37 ppm was significantly decreased, that’s likely 
17 because the plenty of PEG chain decreased the sensitivity of 1H NMR. The structure change 
18 was further characterized by fluorescent spectrophotometer.
19 As shown in Fig 1d, our developed PAMAM exhibited green fluorescence due to the n-π* 
20 transition of the C=N bonds in the formed Schiff bases, showing similar excitation and 
21 emission spectra as our previously reported acetaldehyde modified-cystine (AC)12. No 
22 emission was detected with the original G5 at 485 nm excitation (Fig S5), suggesting that the 
23 fluorescence of F-G5-PEG was only due to the formation of the C=N bonds in the formed 
24 Schiff bases. We further tested the fluorescence intensity of F-G5-PEG at three different pH 
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1 values (pH 7.4, 6.0, and 5.0) and verified that the fluorescence of F-G5-PEG was pH-
2 independent (Fig S4), suggesting that our label free fluorescent PAMAM could be generally 
3 applied to biological systems since the fluorescence will not be adversely affected by differing 
4 pH levels present in sub-cellular organelles. The long-term stability assay (shown in Fig S4) 
5 demonstrated a marginal fluorescence intensity reduction during the first 48 h (~5%) followed 
6 by a ~20% fluorescence intensity reduction after 5 days’ continuous incubation, which 
7 suggested that this label-free fluorescent PAMAM maintains excellent biological 
8 environmental stability. We further compared the fluorescence intensity of F-G5 and F-G5-
9 PEG at the same molar concentration (Figure S6b) and found that the PEGylation only slightly 
10 affect the fluorescent properties (less than 5%), suggesting that the PEGylation of F-G5 
11 wouldn’t change the Schiff base structure. The sufficient fluorescence intensity of F-G5-PEG 
12 makes it an excellent inherent fluorescent material for further biological applications. 
13 The molecular size of G5, F-G5 and F-G5-PEG was further analyzed by size exclusion 
14 chromatography (SEC) with ENrichTMSEC650 High-Resolution Size Exclusion Columns. We 
15 used BSA as a reference macromolecular with the number size distribution of 8.1±0.9 nm 
16 (acquired by DLS in PBS). As shown in Fig 2, the elution time of G5 was slightly later than 
17 that of BSA and earlier than F-G5, indicating that the molecular size of G5, F-G5 were 
18 following the order that BSA (8.1 nm) >G5>F-G5. The elution time of F-G5-PEG was slightly 
19 earlier than that of BSA, which was mainly because the conjugated PEG increased the total 
20 molecular size of F-G5. The results of SEC were consistent with the DLS results, which implies 
21 that the G5, F-G5, F-G5-PEG were most likely dispersed in PBS buffer as single molecular. 
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1
2 Figure 1. The physical and fluorescence characteristics of modified PAMAM, (a) TEM image 
3 of F-G5-PEG in aqueous solutions (The insets showed the digital images of samples), Bar = 
4 0.1 µm; (b) The size distribution of G5, F-G5 and F-G5-PEG by DLS by number distribution 
5 (in PBS); (c) The zetapotential of G5, F-G5 and F-G5-PEG by DLS (in PBS); (d) The excitation 
6 and emission spectra of F-G5-PEG (The insets showed the fluorescent image of F-G5-PEG 
7 under 485 laser excitation). 
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1
2 Figure 2. Chromatograms of PAMAMG5, F-G5, F-G5-PEG and BSA by NGC™ Medium-
3 Pressure Liquid Chromatography Systems. The system elution speed was 1 mL/min.
4 3.2 Biocompatibility of F-PAMAM and PEGylated F-PAMAM
5
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1 Figure 3. Biocompatibility of modified PAMAM. Cellular viability of (a) hCMEC/D3, (b) 
2 SKMel28, (c) HEK293, (d) NSC34 cell lines were treated with cationic PAMAM G5, F-G5 
3 and F-G5-PEG at the concentration range from 2.5 to 100 µg/mL.  (***, p<0.001, **, p<0.01)
4 In DDS, the nanocarriers should be biocompatible with healthy cells. The biocompatibility of 
5 G5, F-G5, F-G5-PEG was evaluated using MTT assays in four different cell lines in the 
6 concentration range of 2.5~100 µg/mL. As shown in Fig 3a-d, after 48 h incubation, a 
7 remarkable decrease in the cytotoxicity of the cationic PAMAM dendrimers was noted when 
8 cells were exposed to the F-G5 and F-G5-PEG, indicated by the average cell viabilities of four 
9 cell lines of above 90%, even at the highest concentration of 100 µg/mL. In great contrast, 
10 commercial G5 showed significant cytotoxicity to all cell lines, revealed by the low cell 
11 viability of below 50% at concentrations of over 10 µg/mL for hCMEC/d3 and SKMel28 cells, 
12 25µg/mL for NSC34 and 50 µg/mL for HEK293. The intrinsic cytotoxicity of PAMAM was 
13 usually caused by the high positive charges of dense terminal amines36. After acetaldehyde 
14 modification amines from PAMAM were replaced by Schiff base terminals and mPEG that 
15 neutralized the overall surface charge and resulted in a significant zeta potential decrease (Fig 
16 1c), thereby substantially alleviated cytotoxicity. These results suggested that the novel F-G5 
17 and F-G5-PEG were potentially safe for biological application. 
18 3.3 Fluorescence tracking of F-G5-PEG in vitro
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1
2 Figure 4. Intracellular tracking of F-G5-PEG (nanocarrier) was assessed in SKMEL28 cell line 
3 by confocal microscopy. Live cell imaging was taken at 2, 4, 8, 24 h intervals after incubation. 
4 488 and 545 nm laser excitation were used for detecting Hoechst and Cytopainter. Scale bar = 
5 20 µm.
6   The intracellular microenvironment-responsive behaviour of F-G5-PEG was monitored at 
7 different time intervals using fluorescence microscopy. As shown in Fig 4, after 2 h incubation, 
8 very weak green fluorescence signal was obtained. As the incubation period increased to 4 h, 
9 green fluorescent spots started to be observed, indicating some complexes have entered cells 
10 through endocytosis. With further prolonged incubation time to 24 h, very bright green 
11 fluorescence images were obtained, indicating enhanced cell loading. To evaluate the 
12 subcellular localization of F-G5-PEG, the cells were stained with Cytopainter® followed the 
13 manufacturer’s protocol. As seen in Fig 4, at the time point 2, 4 and 8 h, the green signal co-
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1 localization with red signal very well, indicating that the F-G5-PEG was mainly accumulated 
2 in lysosome after endocytosis. After 24 h incubation, some F-G5-PEG formed to bright green 
3 granules around cell edge, which may be caused by the exocytosis of those granules. However, 
4 after 24 h incubation, most of F-G5-PEG was still co-localization with lysosome. These studies 
5 suggested that the strong green signals emitted by F-G5-PEG could potentially be used as a 
6 tool for intracellular real-time tracking and also for exploring cellular uptake mechanisms. 
7 3.4 Drug Loading and Release 
8 Table 1. Drug encapsulation efficiency and physical properties of G5/DOX and F-G5-
9 PEG/DOX compositions
Sample TEA:DOX·HCl
(mol:mol)
Sizea, nm Zeta, 
mV
EEb, % LEc,%
G5/DOX 5:1 / / 78.6±4.1 13.6±0.7
F-G5-
PEG/DOX-1 5:1 59.5±7.3 6.5±0.8 94.5±2.8 7.3±0.2
F-G5-
PEG/DOX-2 7.5:1 81.9±2.2 6.3±0.6 91.2±2.3 7.0±0.2
F-G5-
PEG/DOX-3 10:1 127.9±1.6 8.2±1.0 84.5±3.6 6.5±0.3
10 a: Statistics by Z-average
11 b: EE=Encapsulation efficiency (EE) = 100, Wt is the total DOX weight used for drug loading and Wo is 
WoWt ×
12 the weight of encapsulated DOX, respectively.
13 c: LE= drug loading efficiency (LE)= 100, Wp is the total PAMAM weight used for drug loading.
WoWt + Wp ×
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1
2 Figure 5. Drug release profile of (a) F-G5-PEG/DOX-1, (b) F-G5-PEG/DOX-2 and (c) F-G5-
3 PEG/DOX-3 in PBS buffer solution with different pH value. Free DOX was used for 
4 comparison. 
5   DOX was efficiently encapsulated into F-G5-PEG using a solvent-displacement 
6 (precipitation) method. Typically, TEA (Triethylamine) was used to neutralize DOX 
7 hydrochloride so that it could be  loaded inside the PAMAM hydrophobic cavity37. A simple 
8 method to achieve high doxorubicin loading in biodegradable polymersomes was previously 
9 reported and demonstrated that  pH conditions had a strong influence on drug loading capacity 
10 and release38. Similarly, we used a highly volatile organic base (TEA) to control drug loading 
11 by modulating pH conditions. We also explored the effect of molar ratio TEA to DOX·HCl, 
12 using 5:1, 7.5:1, 10:1 as F-G5-PEG/DOX-1, -2, -3 respectively. The size and zetapotential of 
13 drug loaded nanoparticles were measured with DLS. As shown in Table 1, after drug loading, 
14 the size of F-G5-PEG/DOX composites increased dramatically compared with the carrier F-
15 G5-PEG. Meanwhile, a higher TEA to DOX·HCl molar ratio resulted in a larger particle size. 
16 No obvious change in zetapotential were detected for all F-G5-PEG/DOX compositions, 
17 compared to the drug carrier F-G5-PEG. Presumably, DOX mostly accumulated inside the 
18 PAMAM. In our study, non-PEGylated F-G5 was also used to load DOX. However, the F-
19 G5/DOX system was not stable in serum-containing medium and precipitation was evident by 
20 upright microscopy (Olympus). Additionally, a large size increase was also detected by DLS 
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1 (Table S1) after mixing F-G5/DOX with 10% serum, reflecting the very smooth surface of 
2 non-PEGylated F-G5/DOX. The smooth surface of F-G5/DOX composites and extremely low 
3 surface charge significantly impaired steric stability, leading to aggregation of F-G5/DOX in 
4 serum-containing media39. However, with PEGylation, the F-G5-PEG/DOX system was stable 
5 in serum-containing media, and no increased particle size were detected by DLS (Table S1) 
6 during the observation period. These results were consistent with the use of PEG to improve 
7 steric hindrance and enhanced material stability in biological fluids40.
8   Drug loading efficiency was determined by measuring the precipitated un-loaded DOX via 
9 UV-vis spectrometry. As shown in Table 1, F-G5-PEG/DOX-1 presented the highest drug EE 
10 (encapsulation efficiency) (94.5±2.8%) while F-G5-PEG/DOX-3 only yielded 84.5±3.6% drug 
11 EE. The higher drug EE of F-G5-PEG/DOX-1 may be explained by the lower TEA to DOX 
12 molar ratio resulted in relative lower initial pH that slowed down the formation of dimer or 
13 multimer of DOX, thereby affording more time for DOX to assemble inside the PAMAM 
14 hydrophobic cavity. It was noteworthy that all of the F-G5-PEG/DOX compositions possessed 
15 more competitive drug EE than commercial PAMAM G5 (78.6±4.1%), the higher drug 
16 encapsulation efficiency of F-G5-PEG/DOX over G5/DOX might be that the Schiff-base 
17 terminals and PEG terminals form a protection shell, which can prevent DOX diffuse freely 
18 from dendrimer interior to outside bulk solution.
19   For antitumor therapeutic applications, the encapsulated DOX should be effectively released 
20 into the cytoplasm to reach the nucleus to exert its biological activity. To understand the drug 
21 release process, we investigated the cumulative release profile of F-G5-PEG/DOX, in PBS at 
22 different pH values (7.2, 6.5, 5.0). The results shown in Fig 5 indicated that DOX was 
23 sustainably released from F-G5-PEG/DOX in PBS solution at all pH values for 72 h. In 
24 comparison, free DOX drug was ‘burst released’ whereby almost all DOX was released within 
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1 2 h. The release of DOX from F-G5-PEG was enhanced by decreasing the pH value, revealing 
2 that the F-G5-PEG/DOX is pH sensitive. We further noticed that the drug release kinetics of 
3 the three types of F-G5-PEG/DOX were strongly associated with the initial molar ratio of TEA 
4 to DOX·HCl, reflecting the different DOX aggregation characteristics of different formulations 
5 (Table 1) as the drug release rate was strongly associated with the solubilization of the 
6 aggregated molecules and drug diffusion. Additionally, the size of drug loaded nanocarrier will 
7 also affect the drug release rate, as smaller sizes have decreased diffusion distance which results 
8 in a faster release rate.
9     Fluorescence spectra can reflect the aggregation state of fluorescent molecules. DOX 
10 contains a chromophore composed of three aromatic hydroxyanthraquinonic rings 41, which 
11 can be used to monitor interactions with itself or other molecules. As shown in Fig S5, a 
12 remarkable decrease in fluorescence intensity of peaks at 550 and 595 nm were observed with 
13 the F-G5-PEG/DOX-3 compared to the equivalent amount of free DOX·HCl. This was a 
14 typical self-quenching that resulted from increased local concentrations42. In F-G5-PEG/DOX-
15 3 composite, a higher TEA to DOX·HCl molar ratio resulted in a relatively higher initial pH, 
16 which facilitated dimer or multimer formation of DOX, generating a relative higher DOX local 
17 concentration and in turn leading to decreased fluorescence intensity. Meanwhile, the stronger 
18 molecular interactions would also result in a relative slower drug solubilization and diffusion 
19 rate leading to a slower drug release speed. These considerations mean that fluorescence 
20 spectra are valuable tools enabling the prediction of drug release kinetics.
21 3.5 Intracellular Drug Delivery and Therapeutic Efficacy
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1
2 Figure 6. (a) Confocal microscopy images of SKMEL28 cells after 4 h culture in the presence 
3 of free DOX·HCl, DOX (TEA treated, hydrophobic DOX), G5/DOX, F-G5-PEG/DOX-1with 
4 an equivalent amount of DOX (2.5 μg/mL). Bar =50 μm; (b) (c) Cell cytometry assay of SK 
5 MEL 28 cells after 4 h culture in the presence of free DOX·HCl, DOX, G5/DOX, F-G5-
6 PEG/DOX-1with an equivalent amount of DOX (5 μg/mL); (d) Cancer cell cytotoxicity were 
7 assessed using SK MEL 28 cells. Free DOX· HCl, DOX (TEA treated), G5/DOX, F-G5-
8 PEG/DOX with an equivalent amount of DOX were added into the cell culture medium, 
9 respectively. The cell viability was tested after 48 h incubation with different formulations. 
10 (***, p<0.001).
Page 23 of 34
ACS Paragon Plus Environment
Biomacromolecules
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24
1 Drug carriers should be effectively taken up and deliver active drug into the cells. As DOX is 
2 fluorescent (ex/em=490/590), its internalization by SKMEL28 cells can be monitored by 
3 fluorescence microscopy. As shown in Fig 6a, no green fluorescence was evident from free 
4 DOX or G5/DOX. This confirmed that the green fluorescence must be resulting from the label-
5 free fluorescent nanocarrier. For F-G5-PEG/DOX-1, a much brighter red fluorescence was 
6 observed (mostly in the nucleus) compared to hydrophobic DOX or G5/DOX. This higher 
7 nuclear DOX accumulation could be mainly attributed to the more efficient cell uptake of the 
8 F-G5-PEG/DOX-1 (Fig 6a), as well as enhanced DOX release from the endolysosomal 
9 compartments to nucleus as the nanocarrier F-G5-PEG was mainly trapped in the 
10 endolysosomal compartments (Fig 4) and the low pH in the endolysosomal compartments 
11 facilitated intracellular drug release (Fig 3a). At the same time, from the in vitro drug release 
12 experiment, it was clearly shown that about 45% DOX released from the F-G5-PEG/DOX-1 
13 during the first 4 hours. This proved that the extra cellular drug release from F-G5-PEG/DOX 
14 might also improve the intracellular DOX accumulation. Additionally, the endocytosis of free 
15 form hydrophobic DOX was very low, reflecting that the F-G5-PEG/DOX composites indeed 
16 improved the solubility of hydrophobic drugs. We further compared the nanocarrier and drug 
17 uptake between different F-G5-PEG/DOX compositions via confocal microscopy. The images 
18 in Fig S6a showed weaker green and red signals from F-G5-PEG/DOX-2 and F-G5-
19 PEG/DOX-3 treated cells compared to F-G5-PEG/DOX-1 treated cells, indicating less cell 
20 uptake of both nanocarrier and drug for F-G5-PEG/DOX-2 and F-G5-PEG/DOX-3. The higher 
21 nanocarrier uptake of F-G5-PEG/DOX-1 most likely reflected the relatively smaller size of the 
22 particles, which were more easily taken up by the cells. The higher DOX accumulation in 
23 nucleus of F-G5-PEG/DOX-1 treatment was most likely attributed to the relatively higher 
24 composition uptake and faster drug release from the endolysosomal compartments to nucleus 
25 as well as a relative higher extra cellular release of DOX from F-G5-PEG/DOX-1.  
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1   Flow cytometry was used to quantitatively study cell uptake of the compounds. As shown in 
2 Fig 6b, Fig S6b and Fig S7a, a higher DOX uptake was achieved by F-G5-PEG/DOX-1 
3 compared to free hydrophobic DOX or G5/DOX (5.2 and 3.7times, respectively). Nanocarrier 
4 and drug uptake between different F-G5-PEG/DOX compositions were shown in Fig S6b-c 
5 and Fig S7a-b, F-G5-PEG/DOX-2 and F-G5-PEG/DOX-3 showed 39.2% and 59.7% less 
6 nanocarrier uptake and 46.7% and 60.8% less DOX uptake, respectively than F-G5-PEG/DOX-
7 1. The flow cytometry results showed similar drug and nanocarrier uptake, agreeing with the 
8 confocal microscopy results and demonstrated that F-G5-PEG was an efficient drug delivery 
9 vehicle for DOX, and F-G5-PEG/DOX-1was the most efficient nanocarrier for in vitro 
10 intracellular drug accumulation. 
11   The cytotoxicity of the DOX-loaded F-G5-PEG was quantitatively evaluated in SKMel28 
12 cells by MTT assay. As shown in Fig 6d, F-G5-PEG/DOX-1showed enhanced cytotoxicity 
13 (IC50=0.174 μg), whereas free hydrophobic DOX induced mild cytotoxicity as expected 
14 (IC50=0.903μg) reflecting lower solubility in cell culture media (Fig 6d). Biocompatibility 
15 experiments revealed that blank F-G5-PEG did not display any cytotoxicity (Fig 3), thereby 
16 demonstrating that cytotoxic effects were only possible when DOX was loaded within the 
17 nanocomposites. Most importantly, even at very low DOX concentration (0.5 μg/mL), F-G5-
18 PEG/DOX-1 could still induce an impressive cytotoxic effect (5.7 ± 0.5% cell viability) relative 
19 to free hydrophobic DOX drug (87.76 ± 3.9 % cell viability), which was comparable to 
20 DOX·HCl molecules. The G5/DOX system showed intermediate cytotoxicity (IC50=0.569 μg) 
21 compared with other compositions. Combined with the drug uptake investigation, these results, 
22 collectively showed that the cytotoxicity was strongly associated with the degree of DOX 
23 uptake by the respective formulations, confirming that the intracellular drug concentration was 
24 crucial for mediating cell death. We further compared the cytotoxicity between different F-G5-
25 PEG/DOX compositions, as shown in Fig S8, F-G5-PEG/DOX-1 exhibited the best cancer cell 
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1 toxicity (IC50=0.174 μg) while F-G5-PEG/DOX-3 held the weakest cancer cell toxicity 
2 (IC50=0.712 μg) and F-G5-PEG/DOX-2 held intermediate cancer cell toxicity (IC50=0.305 
3 μg). The higher therapeutic efficacy of F-G5-PEG/DOX-1 to SKMel28 cells most likely 
4 attributed to the higher drug accumulation in nucleus by effective nanocomposite endocytosis, 
5 pH enhanced drug release as well as relative fast extra cellular drug release.  In this study, the 
6 fast extra cellular release of DOX from F-G5-PEG/DOX-1 indeed improved the therapeutic 
7 efficacy, however, that may also cause side effects, its valuable if the “burst release” can be 
8 avoided. Prospectively, surface cross-linking with biodegradable polymer or surface 
9 conjugation with drugs may be effective approaches to prevent the burst drug release from 
10 PAMAM/drug delivery system43, 44. Supported by our cell uptake data and cancer cell 
11 therapeutic data, we have thereby show that the F-G5-PEG/DOX system may be an improved 
12 drug delivery system for DOX for cancer treatment and provided guidance for other drug 
13 delivery system designs. 
14 4 CONCLUSION
15 In this study, we successfully produced a new label free fluorescent PAMAM with strong green 
16 fluorescence at maximum wavelength ex/em=485/507 nm. The novel fluorescent dendrimer F-
17 G5/F-G5-PEG showed promising biocompatibility and intracellular imaging capability. Anti-
18 cancer drug DOX could be efficiently encapsulated into F-G5-PEG by a solvent-displacement 
19 method. It was notable that the drug release characteristics of F-G5-PEG/DOX was pH 
20 sensitive and the drug release rate was strongly associated to the initial ratio between TEA and 
21 DOX·HCl. Attractively, the F-G5-PEG/DOX system displayed higher cell uptake and more 
22 effective therapeutic efficacy than hydrophobic DOX and G5/DOX alone. The high efficiency 
23 of this new dendritic drug vehicle suggests that further investigation into their development as 
24 carriers is warranted not just for DOX, but also for other clinically important drugs.
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1
2 SUPPORTING INFORMATION
3 Chemical and physical characterization of pristine PAMAM, F-G5 and F-G5-PEG by TEM 
4 images, FT-IR, 1H NMR and Fluorescence spectrophotometry. Fluorescence spectrum of 
5 nanocarrier/DOX nanocomposites. Size distribution of nanocarrier and nanocarrier/DOX 
6 nanocomposites. The data for intracellular drug delivery and therapeutic efficacy.
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